T1	Participants 15 92	Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion
T2	Participants 624 653	patients with symptomatic VMA
T3	Participants 284 364	patient-reported visual function in symptomatic VMA/vitreomacular traction (VMT)
T4	Participants 929 1031	652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 Î¼m or smaller
T5	Participants 1131 1164	Patients with symptomatic VMA/VMT
T6	Participants 1690 1702	464 patients
